CD40LG and neoplasm: When our proprietary CD40L-CD28 CSP is co-expressed with a rTCR specific for a pHLA ligand on tumor cells, four important attributes are displayed by the TCR-T cells: activation of endothelial cells to allow trans-migration of immune cells, activation of TAM, activation of intra-tumoral DC and killing of CD40+ tumor cells.